Across TCGA pan-cancer cohorts, ANKRD20A2P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ANKRD20A2P data layer compared with 20 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ANKRD20A2P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD20A2P expression acts as an unfavorable survival marker.
SKCM are the cancer types where ANKRD20A2P Mutation most reproducibly stratifies survival.